Thomas F. Gajewski is an AbbVie Foundation Professor of Cancer Immunotherapy and Professor in both the Ben May Department for Cancer Research and the Department of Pathology at the University of Chicago. He investigates and develops new treatments for patients with melanoma and in the development of immunotherapies against this disease. Thomas leads the development of immune-based therapies for cancers other than melanoma, using new laboratory data on how the immune system is regulated to develop novel clinical trials.